Skip to search formSkip to main contentSkip to account menu

betrixaban

An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Betrixaban is primarily excreted unchanged in… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzamidesPyridines

Narrower (1)

PRT054021

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians
Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral anticoagulants 
Review
2018
Review
2018
Pharmacokinetic drug interactions of the non‐vitamin K antagonist oral anticoagulants (NOACs)
2018
2018
Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy
Highly Cited
2017
Highly Cited
2017
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism…
Background: Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The… 
Highly Cited
2016
Highly Cited
2016
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
BACKGROUND Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration… 
Review
2014
Review
2014
Reversal of target-specific oral anticoagulants.
Highly Cited
2013
Highly Cited
2013
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Aims Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel oral factor Xa inhibitor… 
Review
2010
Review
2010
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.
Review
2009
Review
2009
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
For the past five decades, there has been little progress in the development of oral anticoagulants, with the choices being… 
Highly Cited
2008
Highly Cited
2008
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)
Summary Betrixaban is an oral direct inhibitor of factor Xa (FXa) being developed for the prevention of venous thromboembolism… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)